LLY vs RTX: Which Is the Better Buy?
Side-by-side comparison of Eli Lilly and Company and RTX Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-06-20.
Eli Lilly and Company · Healthcare
$1,098.13
+16.7% upside to fair value
Grade B
High Quality
VS
RTX Corporation · Industrials
$185.60
-25.2% upside to fair value
Grade D
QuantHub Verdict
LLY has more upside to fair value
(+16.7%).
RTX trades at a lower forward P/E
(34.3x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
LLY |
RTX |
| Current Price |
$1,098.13 |
$185.60 |
| Fair Value Estimate |
$1,281.02 |
$138.81 |
| Upside to Fair Value |
+16.7%
|
-25.2%
|
| Market Cap |
$1,034.2B |
$249.9B |
| Forward P/E |
38.9x
|
34.3x
|
| EV / EBITDA |
32.0x
|
18.3x
|
| Price / Sales |
14.3x
|
2.8x
|
| Price / FCF |
76.2x
|
29.9x
|
| Revenue Growth YoY |
+55.5%
|
+8.7%
|
| Gross Margin |
83.5%
|
20.2%
|
| Operating Margin |
45.9%
|
10.9%
|
| Return on Equity |
101.3%
|
11.2%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
1.31%
|
3.34%
|
| Analyst Consensus |
Strong Buy
|
Buy
|
Investment Thesis
Eli Lilly and Company is a leading healthcare firm specializing in drug manufacturing with a strong competitive moat in GLP-1 diabetes and obesity treatments as well as biologics manufacturing. The company is led by experienced internal management with a proven capital allocation track record. Its revenue growth is exceptionally strong, driven by its cardiometabolic franchise which accounted for …
RTX Corporation is a leading aerospace and defense company with a strong competitive moat driven by scale and an installed base in commercial aerospace via Pratt & Whitney and Collins Aerospace, and defense through Raytheon. The company benefits from a large multi-year backlog of approximately $270 billion supporting steady cash flow and mid-single-digit organic growth. Despite solid revenue grow…
Accumulation Zones
| Metric |
LLY |
RTX |
| Zone Low |
$960.76 |
$104.11 |
| Zone High |
$1,088.87 |
$117.99 |
| In Buy Zone? |
No
|
No
|